Cellular brakes and accelerators shape TB outcomes

Tuberculosis (TB) can behave very differently in people: some infections remain latent or non-progressive, while others develop into active, damaging disease. What drives these divergent outcomes at the cellular level has been unclear. In work led by Selvakumar Subbian, researchers looked for molecular differences linked to progressive versus non-progressive Mycobacterium tuberculosis (Mtb) infection. They focused on immune cells called macrophages and on lung tissue to see which pathways were turned on during infection. The team examined laboratory and clinical Mtb strains known to differ in how aggressively they cause disease — including H37Rv, HN878 and CDC1551 — and they studied infections in rabbit lungs as well as in primary rabbit and human macrophages and human THP-1 cell line-derived macrophages. Across these models they measured markers of immune activation and cell stress. Their central finding is that progressive infection is associated with increased activity of specific genes and pathways: guanylate-binding protein-1 (GBP1), hypoxia-inducible factor 1α (HIF-1α) and heightened NLR family pyrin domain-containing (NLRP3) inflammasome signaling. The study therefore connects particular cellular signals with whether Mtb infection advances or remains contained.

To compare progressive and non-progressive responses, the researchers infected rabbit lungs and several types of macrophages with different Mtb strains and monitored the activity of GBP1, HIF-1α and the NLRP3 inflammasome pathway. They found that infection with the more progressive clinical strain HN878 triggered upregulation of GBP1 and HIF-1α together with elevated NLRP3 inflammasome activation. This cascade was linked to higher mitochondrial stress in the cells and increased rates of apoptosis and necrosis — two forms of cell death — during progressive infection. By contrast, the non-progressive clinical strain CDC1551 produced a much lower activation of these same pathways in rabbit lungs, primary rabbit and human macrophages as well as human THP-1 cell line-derived macrophages. The team also performed infection studies on macrophages knocked-down for HIF-1α or GBP1 expression; these knock-down experiments reduced NLRP3 activation and its downstream effects, confirming that HIF-1α and GBP1 contribute directly to the inflammasome-driven responses observed during progressive Mtb infection.

These findings identify a specific molecular route — HIF-1α- and GBP1-mediated activation of the NLRP3 inflammasome — that differs between progressive and non-progressive Mtb infections. By linking those differences to mitochondrial stress and cell death, the study offers a clearer picture of how the balance of immune signals within macrophages and lung tissue can tip an infection toward active TB or toward containment. For researchers, the results suggest concrete pathways to investigate further when seeking markers that predict disease progression or when exploring ways to modulate the immune response. While this work does not itself test treatments, understanding that HIF-1α and GBP1 influence NLRP3 inflammasome activity provides a focused molecular framework for future research aimed at preventing progression from latent to active TB or at limiting tissue damage during active disease.